The pathophysiology of cardiovascular disease and diabetes: Beyond blood pressure and lipids

Diabetes Spectrum

Volumn 21, Issue 3, 2008, Pages 160-165

  Dokken, Betsy B ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMA PROTEIN; REACTIVE OXYGEN METABOLITE; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL PERMEABILITY; CAPILLARY LEAK SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CORONARY ARTERY BLOOD FLOW; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETOGENESIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOSE RESPONSE; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HIGH RISK PATIENT; HUMAN; HYPERCOAGULABILITY; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LEUKOCYTE ACTIVATION; LIPID OXIDATION; METABOLIC SYNDROME X; MICROANGIOPATHY; MICROCIRCULATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 52649084275     PISSN: 10409165     EISSN: None     Source Type: Journal    
DOI: 10.2337/diaspect.21.3.160     Document Type: Review

References (64)

1. Muhlestein JB, Anderson JL, Horne BD, Lavasani F, Allen-Maycock CA, Bair TL, Pearson RR, Carlquist JF: Effect of fasting glucose levels on mortality rate in patients with and without diabetes mellitus and coronary artery disease undergoing percutaneous coronary intervention. Am Heart J 146:351-358, 2003
2. Thrainsdottir IS, Aspelund T, Thorgeirsson G, Gudnason V, Hardarson T, Malmberg K, Sigurdsson G, Rydén L: The association between glucose abnormalities and heart failure in the population-based Reykjavík Study. Diabetes Care 28:612-616, 2005
3. Nielson C, Lange T: Blood glucose and heart failure in nondiabetic patients. Diabetes Care 28:607-611, 2005
4. The DECODE Study Group.: Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 354:617-621, 1999
5. Merz CN, Buse JB, Tuncer D, Twillman GB: Physician attitudes and practices and patient awareness of the cardiovascular complications of diabetes. J Am Coll Cardiol 40:1877-1881, 2002
6. Garber AJ: Attenuating cardiovascular risk factors in patients with type 2 diabetes. Am Fam Phys 62:2633-2642, 2645-2646, 2002
7. Libby P, Theroux P: Pathophysiology of coronary artery disease. Circulation 111:3481-3488, 2005
8. Fagot-Campagna A, Rolka DB, Beckles GL, Gregg EW, Narayan KM: Prevalence of lipid ablormalities, awareness, and treatment in US adults with diabetes [Abstract]. Diabetes 49 (Suppl. 1):A78, 2000
9. Rosenson RS: Clinical role of LDL and HDL subclasses and apolipoprotein measurement. ACC Curr J Rev May, 2004, p. 33-37
10. Chan AC: Vitamin E and atherosclerosis. J Nutr 128:1593-1596, 1998
11. Napoli C, Triggiani M, Palumbo G, Condorelli M, Chiariello M, Ambrosio G: Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein. Basic Res Cardiol 92:96-105, 1997
12. Bucala R, Makita Z, Koschinski T, Cerami A: Lipid advanced glycosylated pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 91:9441-9445, 1993
13. Shen GX: Lipid disorders in diabetes mellitus and current management. Curr Pharm Analysis 3:17-24, 2007
14. Duell PB, Oram JF, Bierman EL: Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40:377-384, 1991
15. Celermejer D: Endothelial dysfunction: does it matter? J Am Coll Cardiol 30:325-333, 1997
16. Lewis DH: The effect of trauma on the regulation of the microcirculation [Abstract]. Pathophysiol 5 (Suppl. 1):191, 1998
17. Smith SE, Smith SA, Brown PM: Cardiac autonomic dysfunction in patients with diabetic retinopathy. Diabetologia 21:525-528, 1981
18. Ewing DJ, Campbell D, Clarke BF: The natural history of diabetic autonomic neuropathy. Q J Med 49: 95-108, 1980
19. Taskiran M, Fritz-Hansen T, Rasmussen V, Larsson HBW Hilsted J: Decreased myocardial perfusion reserve in diabetic autonomic neuropathy. Diabetes 51:3306-3310, 2002
20. Koh KK, Han SH, Quon MJ: Inflammatory markers and the metabolic syndrome [Abstract]. J Am Coll Cardiol 46:1978-1985, 2005
21. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
22. Williams SB, Goldfine AB, Timimi FK, Ting HH, Roddy MA, Simonson DC, and Creager MA: Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 97:1695-1701, 1998
23. Hayden MR, Sowers JR, Tyagi SC: The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol 4:9-29, 2005
24. Bauer TA, Reusch JEB, Levi M, Regensteiner JG: Skeletal muscle deoxygenation after the onset of moderate exercise suggests slowed microvascular blood flow kinetics in type 2 diabetes. Diabetes Care 30:2880-2985, 2007
25. Tooke JE: Microcirculation and diabetes. British Med Bull 45:206-223, 1989
26. Weir M: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2:581-590, 2007
27. Pickup JC, Mattock MB, Chusney GD, Burt D: NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
28. Festa A, D'Agostino Jr R, Howard G, Mykkänen L, Tracy RP, Haffner SM: Chronic Subclinical inflammation as part of the insulin resistance syndroine. Circulation 102:42-47, 2000
29. Kim J, Koh KK, Quon MJ: The union of vascular and metabolic actions of insulin in sickness and in health. Artericiscler Thromb Vasc Biol 46:1978-1985, 2005
30. Woods M, Mitchell JA, Wood EG, Barker S, Walcot NR, Rees GM, Warner TD: Endothelin-1 is induced by cytokines in human vascular smooth muscle cells: evidence for intracellular endothelin-converting enzyme. Mol Pharmacol 55:902-909, 1999
31. Chung KF, Barnes PJ: Cytokines in asthma. Thorax 54:825-857, 1999
32. Pickup JC, Mattock MB: Activation of the innate immune system as a predictor of cardiovascular mortality in type 2 diabetes mellitus. Diabet Med 20:723-726, 2003
33. Pickup JC, Mattock MB, Chusney GD, Burt D:. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 40:1286-1292, 1997
34. Jarrett RJ, Shipley MJ: Type 2 (non-insulin-dependent) diabetes mellitus and cardiovascular disease: putative association via common antecedents; further evidence from the Whitehall Study. Diabetalogia 31:737-740, 1988
35. Trayhurn P, Wood JS: Signalling role of adipose tissue: adipokines and inflammation in obesity. Biochcm Soc Trans 33:1078-1081, 2005
36. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257:79-83, 1999
37. Testa CM. Mitochondria in movement disorders. In Movement Disorders, 2nd ed. Watts RL, Koller WC, Eds. McGraw Hill, New York. 2004, p. 61-86
38. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, Tritschler H, Rosen P, Halliwell B, Betteridge DJ: Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 40:647-653, 1997
39. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664-671, 2004
40. Nishikawa T, Araki E: Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antiox Redox Sig 9:343-353, 2007
41. Sohal RS, Sohal BH: Hydrogen peroxide release by mitochondria increases during aging. Mech Aging Dev 57:187-202, 1991
42. Brownlee M: The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54:1615-1625, 2005
43. Hokama J, Ritter LS, Davis-Gorman G, Cimetta AD, Copeland JG, McDonagh PF: Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia [Abstract]. J Diabetes Comp 14:96-107, 2000
44. Freedman SF, Hatchell DL: Enhanced superoxide radical production by stimulated polymorphonuclear leukocytes in a cat model of diabetes [Abstract]. Exp Eye Res 55:767-773, 1992
45. Gu K, Cowie CC, Harris ML: Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1993. Diabetes Care 21:1138-1145, 1998
46. Weyrich AS, Prescott SM, Zimmerman GA: Platelets, endothelial cells, inflammatory chemokines, and restenosis: signaling in the vascular play book. Circulation 106: 1433-1435, 2002
47. Carr ME: Diabetes: a hypercoagulable state. J Diabetes Comp 15:44-54, 2001
48. Evangelista V, Totani L, Rotondo S, Lorenzet R, Tognoni G, De Berardis G, Nicolucci A: Prevention of cardiovascular disease in type 2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8-16, 2005
49. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldmanmd AM, Francis GS, Ganiats TG, Goldstein S, Gregoratos G, Jessup ML, Noble RJ, Packer M, Silver MA, Stevenson LW: ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult: executive summary. Circulation 104:2996-3007, 2001
50. Gutierrez C, Blanchard DG: Diastolic heart failure: challenges of diagnosis and treatment. Am Fam Phys 69:2609-2616, 2004
51. Marwick TH: Diabetic heart disease. Heart 92:296-300, 2006
52. Poirier P, Bogaty P, Garneau C, Marois L, Dumesnil JG: Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy. Diabetes Care 24:5-10, 2001
53. Redfield MM, Jacobsen SJ, Burnett JC, Mahoney DW, Bailey KR, & Rodeheffer RJ: Burden of systolic and diastolic ventricular dysfunction in the community. JAMA 289:194-202, 2003
54. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE: Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiol 98:33-39, 2002
55. Kawaguchi M, Techigawara M, Ishihata T, Asakura T, Saito F, Maehara K, Maruyama Y: A comparison of ultrastructural changes on endomyocardial biopsy specimens obtained from patients with diabetes mellitus with and without hypertension. Heart Ves 12:267-274, 1997
56. Pop-Busui R, Kirkwood I, Schmid H, Marinescu V, Schroeder J, Larkin D, Yamada E, Raffel DM, Stevens MJ: Sympathetic dysfunction in type 1 diabetes: association with impaired myocardial blood flow reserve and diastolic dysfunction. J Am Coll Cardiol 44:2368-2374, 2004
57. Galderisi M, Cicala S, Caso R, De Simone L, D'Errico A, Petrocelli A, de Divitiis O: Coronary flow reserve and myocardial diastolic dysfunction in arterial hypertension. Am J Cardiol 90:860-864, 2002
58. Galderisi M: Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler. J Am Coll Cardiol 48:1548-1551, 2006
59. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
60. Devereux RB, Roman MJ, Paranicas M, O'Grady MJ, Lee ET, Welty TK, Fabsitz RR, Robbins D, Rhoades ER, Howard BV: Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 101:2271-2276, 2000
61. Bell DS: Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 18:5708-5714, 2003
62. Boudina S, Abel ED: Mitochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiol 21:250-258, 2005
63. Szabo C: PARP as a drug target for the therapy of diabetic cardiovascular dysfunction. Drug News Persp 15:197-205, 2002
64. Palmiere V, Tracy RP, Roman MJ, Liu JE, Best LG, Bella JN, Robbins DC, Howard BV, Devereux RB: Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes. Diabetes Care 26:2764-2769, 2003